Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...